Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Fumine Tanaka; Ryota Kogue; Masayuki Maeda; Maki Umino; Yasuo Nakai; Atsuro Takeshita; Hajime Sakuma

doi:10.1016/j.radcr.2017.11.007

Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Radiol Case Rep. 2017 Dec 12;13(1):261-264. doi: 10.1016/j.radcr.2017.11.007. eCollection 2018 Feb.

Authors

Fumine Tanaka¹, Ryota Kogue¹, Masayuki Maeda², Maki Umino¹, Yasuo Nakai³, Atsuro Takeshita⁴, Hajime Sakuma¹

Affiliations

¹ Department of Radiology, Mie University School of Medicine, Mie, Japan.
² Department of Advanced Diagnostic Imaging, Mie University School of Medicine, Mie, Japan.
³ Department of Dermatology, Mie University Graduate School of Medicine, Mie, Japan.
⁴ Department of Diabetes and Endocrinology, Mie University School of Medicine, Mie, Japan.

Abstract

Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use, has been frequently reported. We report a case of ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum, identified using 3D fluid-attenuated inversion recovery.

Keywords: 3D FLAIR; Hypophysitis; Ipilimumab; Melanoma; Optic tract.

Publication types

Case Reports